ELVN
Enliven Therapeutics, Inc.- Healthcare
- Biotechnology
- $3.04B market cap
Forecast run · Oct 29, 2026Upside rank 1350 of 3,186
Model Signal
ForecastQ Daily Probabilities
29.1%
57.5%
15.9%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$41.52
Price target$76.29
Implied move+83.7%
Analysts9
ForecastQ Portfolios
ELVN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.